BPGbio is Evaluating BPM31510 Oral Formulation for Sarcopenia.

Sarcopenia is a progressive loss of muscle strength, muscle mass, and physical function that occurs most commonly with aging. It can make everyday activities—such as walking, climbing stairs, rising from a chair, or carrying groceries—more difficult and may increase the risk of falls, fractures, loss of independence, and disability.

Sarcopenia is complex and can result from multiple overlapping factors, including:

• Aging-related changes in muscle biology
• Reduced physical activity or prolonged inactivity
• Poor nutrition or inadequate protein intake
• Chronic inflammation
• Hormonal changes
• Neuromuscular changes
• Intentional or unintentional weight loss
• Mitochondrial dysfunction and reduced muscle energy metabolism

Symptoms of sarcopenia often develop gradually and may worsen over time. While many people assume these changes are simply part of aging, they may reflect progressive muscle loss and declining muscle function.

Common signs and symptoms of sarcopenia may include:

• Muscle weakness
• Loss of muscle mass
• Reduced stamina or endurance
• Difficulty walking or climbing stairs
• Slower walking speed
• Trouble standing up from a chair
• Poor balance or increased risk of falls
• Fatigue during routine activities
• Difficulty carrying groceries or lifting objects
• Reduced physical independence

Some people may also notice they tire more easily during everyday activities or experience a decline in mobility and overall physical performance.

If left unaddressed, sarcopenia may contribute to frailty, falls, hospitalization, and loss of independence in older adults.

Skeletal muscle requires large amounts of energy to support movement, strength, repair, and endurance. Mitochondria—often referred to as the energy-producing structures within cells—play a central role in generating this energy through the production of adenosine triphosphate (ATP), the molecule that powers muscle function.

As people age, mitochondrial function can decline, which may reduce the ability of muscle cells to efficiently produce energy and respond to physical stress. A growing body of research suggests that mitochondrial dysfunction, impaired muscle metabolism, oxidative stress, and inflammation may contribute to the development and progression of sarcopenia.

A key molecule involved in mitochondrial energy production is Coenzyme Q₁₀ (CoQ₁₀), a naturally occurring compound found in the inner mitochondrial membrane that helps drive the electron transport chain, a critical process for ATP generation. Some studies have suggested that lower CoQ₁₀ levels may be associated with aging-related declines in muscle health and physical function, increasing scientific interest in the role of mitochondrial biology in sarcopenia.

BPM31510 in Sarcopenia

BPM31510 is an investigational therapeutic containing oxidized CoQ₁₀ formulated using BPGbio’s proprietary lipid nanodispersion technology. The formulation is designed to support delivery of CoQ₁₀ in a pharmaceutical-grade drug product.

BPGbio is initiating a Phase II clinical trial using oral BPM31510, a CoQ₁₀ nano suspension, that will be evaluated for impacting muscle strength, aerobic capacity, and physical function in sarcopenic patients compared to placebo controls.

BPGbio has previously completed an oral dosing Phase I health control volunteer study of BPM31510 demonstrating safety and tolerability.

Please check back for more information about BPGbio’s BPM31510 Sarcopenia trial.

BPM31510 is not yet approved by the FDA